MEBIAS holds a game-changing platform to discover next generation, GPCR drugs devoid of on-target side effects.
G-protein Coupled Receptor (GPCR) therapeutics comprise ~30% of current prescribed drugs. Mebias’ understanding of protein dynamics of GPCRs offers a unique advantage. Given our experience and access to two key technologies – native GPCR purification and protein nuclear magnetic resonance – our approach offers resolution to identify agonists that is lacking in other methodologies. We have delivered a series of biased mu opioid receptor scaffolds among which is an clinical stage compound. The Mebias platform significantly decreases the time and costs to deliver optimized leads.
Our initial areas of focus are CNS/Pain, OUD, Metabolic, and Inflammatory related disorders.
Expertise / Assets
• Rapid identification and optimization of IND candidates devoid of on-target adverse effects, enabled by a fully validated assay suite which identifies ligand-induced dynamic conformation of GPCR signaling.
• Differentiated mu-opioid receptor agonist (MEB-1170) for the treatment of OUD and pain (lacking respiratory depression/GI motility issues/tolerance and does not demonstrate potential for abuse liability)
Business Proposal
• Seeking co-development and/or license our mu-opioid drug candidates
• Research funding/collaboration for lead discovery of additional targets in selected disease areas
Company Details
- Employees
- 4
- Founded
- -
- Address
- Philadelphia, Pa
- Phone
- (267)536-4125
- pr****@****ery.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- mebiasdiscovery.com
- HQ
- Philadelphia, PA
Mebias Discovery, Inc Questions
Mebias Discovery, Inc's helpline number is (267)536-4125
Mebias Discovery, Inc's website is mebiasdiscovery.com
Mebias Discovery, Inc's LinkedIn profile is https://www.linkedin.com/company/mebias-discovery
Mebias Discovery, Inc has
4 employees.
View email and phone details for 4
employees at Mebias Discovery, Inc.
Mebias Discovery, Inc's industry is
Biotechnology Research
Mebias Discovery, Inc's top competitors are
Fore Biotherapeutics,
Teva Pharmaceuticals,
Carisma Therapeutics,
Longevity Biotech,
Eisai Us,
Integral Molecular,
Insilico Medicine,
Navrogen,
Interius Biotherapeutics,
Passage Bio.
Mebias Discovery, Inc's support email address is protein.dynamics@mebiasdiscovery.com
Mebias Discovery, Inc's categories are Biotechnology Research
Mebias Discovery, Inc's founding year is 2015
